Abstract:Major depressive disorder (MDD) is one of the most disabling psychiatric disorders. Approximately one‐third of the patients with MDD are treatment resistant to the current antidepressants. There is also a significant therapeutic time lag of weeks to months. Furthermore, depression in patients with bipolar disorder (BD) is typically poorly responsive to antidepressants. Therefore, there exists an unmet medical need for rapidly acting antidepressants with beneficial effects in treatment‐resistant patients with MDD or BD. Accumulating evidence suggests that the N‐methyl‐D‐aspartate receptor (NMDAR) antagonist ketamine produces rapid and sustained antidepressant effects in treatment‐resistant patients with MDD or BD. Ketamine is a racemic mixture comprising equal parts of (R)‐ketamine (or arketamine) and (S)‐ketamine (or esketamine). Because (S)‐ketamine has higher affinity for NMDAR than (R)‐ketamine, esketamine was developed as an antidepressant. On March 5, 2019, esketamine nasal spray has been approved by the US Food Drug Administration. However, preclinical data suggest that (R)‐ketamine exerts greater potency and longer‐lasting antidepressant effects than (S)‐ketamine in animal models of depression and that (R)‐ketamine has less detrimental side effects than (R,S)‐ketamine or (S)‐ketamine. In this article, the author reviews the historical overview of the antidepressant actions of enantiomers of ketamine and its major metabolites norketamine and hydroxynorketamine. Furthermore, the author discussed the other potential rapid‐acting antidepressant candidates [i.e., NMDAR antagonists and modulators, low‐voltage‐sensitive T‐type calcium channel inhibitor, potassium channel Kir4.1 inhibitor, negative modulators of γ‐aminobutyric acid, type A (GABAA) receptors] to compare them with ketamine. Moreover, the molecular and cellular mechanisms of ketamine's antidepressant effects have been discussed.This article is protected by copyright. All rights reserved.

Lateral Habenular Burst Firing As a Target of the Rapid Antidepressant Effects of Ketamine.

Ketamine blocks bursting in the lateral habenula to rapidly relieve depression

Ketamine Exerts Its Sustained Antidepressant Effects Via Cell-Type-specific Regulation of Kcnq2.

Ketamine May Exert Rapid Antidepressant Effects Through Modulation of Neuroplasticity, Autophagy, and Ferroptosis in the Habenular Nucleus.

Decoding Depression: Insights from Glial and Ketamine Regulation of Neuronal Burst Firing in Lateral Habenula.

Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics

Ketamine and the Future of Rapid-Acting Antidepressants

Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

Brain region-specific action of ketamine as a rapid antidepressant

Sustained Antidepressant Effect of Ketamine Through NMDAR Trapping in the LHb

Neurobiology of the Rapid-Acting Antidepressant Effects of Ketamine: Impact and Opportunities

Synaptic basis of rapid antidepressant action

Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments

Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine

A role of GABAA receptor 1 subunit in the hippocampus for rapid-acting antidepressant-like effects of ketamine

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

Ketamine's rapid and sustained antidepressant effects are driven by distinct mechanisms

KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS

The Neurobiological Mechanism Underlying Ketamine’s Rapid-Acting Antidepressant Effect